Yu-Ning Li, Jia-Lin Su, Shu-Hua Tan, Xing-Long Chen, Tian-Li Cheng, Zhou Jiang, Yong-Zhong Luo, Le-Meng Zhang
BACKGROUND: Non-small cell lung cancer (NSCLC) is the primary form of lung cancer, and the combination of chemotherapy with immunotherapy offers promising treatment options for patients suffering from this disease. However, the emergence of drug resistance significantly limits the effectiveness of these therapeutic strategies. Consequently, it is imperative to devise methods for accurately detecting and evaluating the efficacy of these treatments. AIM: To identify the metabolic signatures associated with neutrophil extracellular traps (NETs) and chemoimmunotherapy efficacy in NSCLC patients...
July 16, 2024: World Journal of Clinical Cases
Mélissa Boisclair, Charlotte Robitaille, Adrian Budhram, Amy Kunchok, Hugo Chapdelaine, Laurent Létourneau-Guillon, Gabrielle Macaron, Catherine Larochelle
INTRODUCTION: We report a challenging case of autoimmune encephalitis in a patient with a thymoma harboring titin and acetylcholine receptor antibodies, who experienced multiple relapses despite thymectomy and aggressive first-line immunotherapy, and for whom GABAA receptor antibodies were ultimately identified. CASE PRESENTATION: This 40-year-old man presented with headaches, weakness, diplopia, hearing loss, and seizures progressing to status epilepticus. Brain MRI showed multifocal cortical and subcortical T2/fluid attenuated inversion recovery hyperintense lesions without enhancement...
2024: Case Reports in Neurology
Jiahui Li, Zihe Qiao, Yuwei Li, Xinyan Lu, Tingru Shao, Xiaozhi Lv
BACKGROUND: Oral squamous cell carcinoma (OSCC) stands as the predominant form of oral cancer, marked by a poor prognosis. Ferroptosis, a type of programmed cell death, plays a critical role in the initiation and progression of various cancers. Long non-coding RNAs (lncRNAs) are prominent in modulating cancer development. Nevertheless, the prognostic significance of ferroptosis-related lncRNAs (FRLs) in OSCC remains inadequately explored. This study aims to develop a predictive signature based on FRLs to forecast the prognosis of OSCC patients...
June 30, 2024: Heliyon
Chengyan Jin, Yan Zhang, Baofeng Li, Tianci Gao, Bin Wang, Peiyan Hua
Tumor mRNA vaccines present a personalized approach in cancer immunotherapy, encoding distinct tumor antigens to evoke robust immune responses and offering the potential against emerging tumor variants. Despite this, the clinical advancement of tumor mRNA vaccines has been hampered by their limited delivery capacity and inefficient activation of antigen-presenting cells (APCs). Herein, we employed microfluidics technology to engineer mannose-modified lipid-based nanovaccines for specifically targeting APCs...
August 2024: Materials today. Bio
Jian Wang, Haiming Jiang
Purpose: To screen mitochondrial function-associated PCD-related biomarkers and construct a risk model for predicting the prognosis of early breast cancer. Methods: Data on gene expression levels and clinical information were obtained from the TCGA database, and GSE42568 and GSE58812 datasets were obtained from GEO database. The mitochondrial function-associated programmed cell death (PCD) related genes in early breast cancer were identified, then LASSO logistic regression, SVM-RFE, random forest (RF), and multiple Cox logistic regression analysis were employed to construct a prognostic risk model...
2024: Frontiers in Genetics
Jie Cao, Yuanjun Liu, Cheng Lu
BACKGROUND: Nuclear protein in testis (NUT) carcinoma (NC) is a rare, highly aggressive neoplasm, usually accompanying with NUTM1 (NUT midline carcinoma family member 1) gene fusions. Primary thyroid NC is clinically rare and to date there is no established treatment guideline available for NC. We report a case of histopathologically confirmed thyroid NC and provide reference for diagnosis and treatment. CASE DESCRIPTION: We presented a 32-year-old female admitted to hospital with "painful neck swelling and progressive dysphagia"...
June 30, 2024: Gland Surgery
Andriani Charpidou, Georgia Hardavella, Efimia Boutsikou, Emmanouil Panagiotou, Gökçen Ömeroğlu Simsek, Koen Verbeke, Daniela Xhemalaj, Joanna Domagała-Kulawik
The progress in lung cancer treatment is closely interlinked with the progress in diagnostic methods. There are four steps before commencing lung cancer treatment: estimation of the patient's performance status, assessment of disease stage (tumour, node, metastasis), recognition of histological subtype, and detection of biomarkers. The resection rate in lung cancer is <30% and >70% of patients need systemic therapy, which is individually adjusted. Accurate histological diagnosis is very important and it is the basis of further molecular diagnosis...
June 2024: Breathe
Qian Li, Mei Liu, Yunxia Liu, Feng Shi, Shan Yuan, Guojie Di, Haobin Jin, Yaru Shi, Wen Zhang, Zhe Yang
INTRODUCTION: Although programmed death ligand 1 (PD-L1) inhibitor plus chemotherapy regimen is a promising strategy for malignant tumors, it can induce significant immune-related adverse events, such as immune-related pneumonitis. Here, we report the first case of lethal immune-related pneumonitis in an Asian patient receiving anti-PD-L1 treatment. CASE PRESENTATION: A 68-year-old man was diagnosed with small cell lung cancer and interstitial pneumonia. After his pulmonary infection was relieved by comprehensive treatment, the patient received first-line treatment with durvalumab plus etoposide and carboplatin...
2024: Case Reports in Oncology
Zun Mao, Zhixiang Gao, Ruyu Long, Huimin Guo, Long Chen, Sheng Huan, Guoping Yin
BACKGROUND AND AIMS: The mitotic catastrophe (MC) pathway plays an important role in hepatocellular carcinoma (HCC) progression and tumor microenvironment (TME) regulation. However, the mechanisms linking MC heterogeneity to immune evasion and treatment response remain unclear. METHODS: Based on 94 previously published highly correlated genes for MC, HCC patients' data from the Cancer Genome Atlas (TCGA) and changes in immune signatures and prognostic stratification were studied...
2024: Frontiers in Immunology
Yu Cao, Chang Lu, Narasimha M Beeraka, Sergey Efetov, Mikhail Enikeev, Yu Fu, Xinyi Yang, Basappa Basappa, Mingze He, Zhi Li
Ferroptosis induces significant changes in mitochondrial morphology, including membrane condensation, volume reduction, cristae alteration, and outer membrane rupture, affecting mitochondrial function and cellular fate. Recent reports have described the intrinsic cellular iron metabolism and its intricate connection to ferroptosis, a significant kind of cell death characterized by iron dependence and oxidative stress regulation. Furthermore, updated molecular insights have elucidated the significance of mitochondria in ferroptosis and its implications in various cancers...
2024: Frontiers in Immunology
Yuanlin Wu, Guangmao Yu, Ketao Jin, Jun Qian
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy...
2024: Frontiers in Immunology
Jin Li, Xu Zhang, Liuke Yang, Youwei Zhu, Rongrong Gao, Tiancheng Zhang, Xuwen Chen, Jun Fu, Gaoyang He, Huijuan Shi, Shenjie Peng, XiaoHua Wu
[This corrects the article DOI: 10.3389/fimmu.2024.1391524.].
2024: Frontiers in Immunology
Chuan Xu, Chaoyang Jiang, Zhihui Li, Hui Gao, Jing Xian, Wenyan Guo, Dan He, Xingchen Peng, Daijun Zhou, Dong Li
Exosomes are nanoscale vesicles of cellular origin. One of the main characteristics of exosomes is their ability to carry a wide range of biomolecules from their parental cells, which are important mediators of intercellular communication and play an important role in physiological and pathological processes. Exosomes have the advantages of biocompatibility, low immunogenicity, and wide biodistribution. As researchers' understanding of exosomes has increased, various strategies have been proposed for their use in diagnosing and treating diseases...
August 2024: MedComm
Harry Wilson, Douglas Macdonald, Kathleen Bryce
INTRODUCTION: Patients with advanced hepatocellular carcinoma (HCC) have limited treatment options in the context of decompensated cirrhosis. HCC occurs in patients with hepatitis C virus (HCV) infection and cirrhosis at 1-4% per year. Direct-acting antiviral (DAA) efficacy is decreased in the presence of HCC. We present a case where immunotherapy may have resulted in HCV clearance, when DAA therapy had been ineffective. We hypothesise that immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway can reverse T-cell exhaustion and aid in the clearance of chronic HCV...
2024: Case Reports in Gastroenterology
Leticia Szadai, Aron Bartha, Indira Pla Parada, Alexandra I T Lakatos, Dorottya M P Pál, Anna Sára Lengyel, Natália Pinto de Almeida, Ágnes Judit Jánosi, Fábio Nogueira, Beata Szeitz, Viktória Doma, Nicole Woldmar, Jéssica Guedes, Zsuzsanna Ujfaludi, Zoltán Gábor Pahi, Tibor Pankotai, Yonghyo Kim, Balázs Győrffy, Bo Baldetorp, Charlotte Welinder, A Marcell Szasz, Lazaro Betancourt, Jeovanis Gil, Roger Appelqvist, Ho Jeong Kwon, Sarolta Kárpáti, Magdalena Kuras, Jimmy Rodriguez Murillo, István Balázs Németh, Johan Malm, David Fenyö, Krzysztof Pawłowski, Peter Horvatovich, Elisabet Wieslander, Lajos V Kemény, Gilberto Domont, György Marko-Varga, Aniel Sanchez
INTRODUCTION: While Immune checkpoint inhibition (ICI) therapy shows significant efficacy in metastatic melanoma, only about 50% respond, lacking reliable predictive methods. We introduce a panel of six proteins aimed at predicting response to ICI therapy. METHODS: Evaluating previously reported proteins in two untreated melanoma cohorts, we used a published predictive model (EaSIeR score) to identify potential proteins distinguishing responders and non-responders...
2024: Frontiers in Oncology
Pim J J Damen, Steven H Lin, Peter S N van Rossum
No abstract text is available yet for this article.
2024: Frontiers in Oncology
Yuki Mizutani, Ena Noda, Makoto Kondo, Akinobu Hayashi, Keiichi Yamanaka
INTRODUCTION: Anti-PD-1 immunotherapies enhance T-cell responses against tumor cells by blocking the interaction between PD-1 and its ligand, PD-L1. While these therapies offer significant benefits in treating various malignancies, they can also lead to several immune-related adverse events (irAEs), most notably manifesting in the skin. Lichenoid reactions, eczema, and vitiligo are the three most prevalent forms of cutaneous irAE. CASE PRESENTATION: Here, we report a rare case of a pityriasis lichenoides et varioliformis acuta (PLEVA) that developed during pembrolizumab treatment for invasive bladder cancer...
2024: Case Reports in Dermatology
Babette J A Verkouteren, An K L Reyners, Maureen J B Aarts, Klara Mosterd
INTRODUCTION: Basal cell carcinoma (BCC) is treated with local surgery or noninvasive treatment modalities. If a BCC remains untreated, it can develop into a locally advanced BCC or a metastatic BCC. CASE PRESENTATION: Here we report in detail the management of three complex advanced BCC (aBCC) after treatment failure with vismodegib. On all tumors, next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed; subsequently, patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anticancer drugs based on the molecular tumor profile...
2024: Case Reports in Dermatology
Caroline E Dravillas, Samuel S Coleman, Rebecca Hoyd, Griffin Caryotakis, Louis Denko, Carlos H F Chan, Michelle L Churchman, Nicholas Denko, Rebecca D Dodd, Islam Eljilany, Sheetal Hardikar, Marium Husain, Alexandra P Ikeguchi, Ning Jin, Qin Ma, Martin D McCarter, Afaf E G Osman, Lary A Robinson, Eric A Singer, Gabriel Tinoco, Cornelia M Ulrich, Yousef Zakharia, Daniel Spakowicz, Ahmad A Tarhini, Aik Choon Tan
Emerging evidence supports the important role of the tumor microbiome in oncogenesis, cancer immune phenotype, cancer progression, and treatment outcomes in many malignancies. In this study, we investigated the metastatic melanoma tumor microbiome and potential roles in association with clinical outcomes, such as survival, in patients with metastatic disease treated with immune checkpoint inhibitors (ICIs). Baseline tumor samples were collected from 71 patients with metastatic melanoma before treatment with ICIs...
July 17, 2024: Cancer Res Commun
James P Blackmur, James N Armitage, James O Jones, Antony C P Riddick, Thomas J Mitchell, William H J Ince, Sona Appukutty, Anne Y Warren, Kate Fife, Brent O'Carrigan, Grant D Stewart
No abstract text is available yet for this article.
July 16, 2024: BJU International
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.